北京若生智能科技有限公司
Drug Database
CE

cefazolin dibenzylamine (Daren)

✓ Approved

Pfizer, Inc. · 小分子 · 小分子

什么是 cefazolin dibenzylamine？

cefazolin dibenzylamine 是一种小分子，由Pfizer, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Daren
公司Pfizer, Inc.
药物类别小分子
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Pfizer, Inc.

治疗适应症

cefazolin dibenzylamine 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsUrinary tract infection✓ Approved
Infections and infestationsRespiratory tract infection✓ Approved

相关研究文献

PubMedFederal practitioner : for the health care professionals of the VA, DoD, and PHS2026-09-10

Outcomes From the Use of Cefazolin for Surgical Prophylaxis in Patients Allergic to Penicillin.

Passalacqua Megan M, Knefelkamp Christopher C, Lohmar Haylie H, Kniery Kevin K et al.

For surgical prophylaxis, alternatives to cefazolin are frequently used in patients with penicillin allergy due to the risk of cross-reactivity. This study investigated whether an evidence-based prescribing tool would result in an increased number of patients with a documented penicillin allergy receiving cefazolin for periprocedural antibiotic prophylaxis without an increase in allergic reactions. This single-center, retrospective chart review analyzed patients with a documented penicillin allergy who received periprocedural antibiotics between February 1, 2023, and January 31, 2024. The primary objective was to determine the incidence of allergic reactions in patients with a documented penicillin allergy who received cefazolin perioperatively. Secondary outcomes included the appropriateness of antibiotic regimens in congruence with American System of Health Pharmacists (ASHP) recommendations, incidence of surgical site infections (SSIs), incidence of adverse drug reactions in those with a history of anaphylaxis vs nonanaphylaxis allergy, incidence of allergic reactions requiring interventions, and incidence of acute kidney injury (AKI). There were 197 surgical procedures in patients with a documented penicillin allergy. No allergic reactions were reported. In the cefazolin group, 126 antibiotic regimens (99.2%) were in congruence with ASHP recommendations; all regimens were in congruence with ASHP recommendations in the cefazolin plus gentamicin group; and 58 (86.6%) were in congruence with ASHP recommendations in the other antibiotic group. There was no incidence of SSI in the cefazolin or cefazolin plus gentamicin group, and 3 incidents in the other antibiotic group. One instance of AKI was reported in the cefazolin group, and none were reported in cefazolin plus gentamicin or the other antibiotic group. This study reported similar outcomes to previously published research, which supports the perioperative use of cefazolin in patients allergic to penicillin, including those with a history of anaphylaxis.

PMID 42719389
阅读全文 →
PubMedFood research international (Ottawa, Ont.)2026-09-07

Genomic and One Health insights into Vibrio parahaemolyticus from environmental, seafood and clinical sources.

Chen Xiao X, Meng Xiaohua X, Wang Ruonan R, Guo Wei W et al.

Vibrio parahaemolyticus is a leading cause of seafood-borne gastroenteritis worldwide, with climate warming facilitating its spread to high-latitude areas. In this study, we analyzed 212 genomes of environmental and seafood-associated isolates collected from seven cities in Zhejiang Province, China (2019-2024), alongside 228 clinical genomes from public databases. The 212 isolates were assigned to 172 sequence types (STs), with ST490 being the most frequent (5/212, 2.36%). Forty-four serotypes were identified, dominated by OL3:KUT (12.68%). High ST and serotype diversity were observed across different sample types and sources, with median pairwise single nucleotide polymorphisms (SNPs) ranging from 57,431 to 58,378, indicating comparable genetic diversity across groups. All isolates carried tlh and T3SS1 but lacked tdh and T3SS2. Resistance rates against ampicillin and cefazolin were 54.72% (116/212) and 44.34% (94/212), respectively, with multidrug resistance (MDR) detected in nine isolates, predominantly from seafood (7/9). A total of 63 distinct antimicrobial resistance genes (ARGs) spanning seven classes were identified. Isolates from aquaculture farms and wet markets exhibited greater resistance category diversity and higher ARG carriage than those from coastal or riverine sites. In contrast, the 228 clinical isolates harbored only 25 ARGs across two classes, with a significantly lower proportion of isolates carrying multiple ARG classes (0.44% vs. 6.13%, P < 0.001). Human isolates formed tighter phylogenetic clusters, although a minority were closely related to environmental/foodborne strains. Overall, our findings demonstrate the genetic diversity and resistance potential of V. parahaemolyticus across environmental, seafood, and clinical sources, highlighting the importance of the One Health approach to comprehensive public health risk assessment.

PMID 42705734
阅读全文 →
PubMedJournal of the College of Physicians and Surgeons--Pakistan : JCPSP2026-09-05

Appropriateness of Antibiotic Dosing in Patients with Augmented Renal Clearance in Cardiovascular Surgery and Coronary Intensive Care Units.

Kinal Ayse Gul Kocoglu AGK, Ayhan Yunus Emre YE

To evaluate the appropriateness of antibiotic dosing in patients with augmented renal clearance (ARC) admitted to the cardiovascular surgery intensive care unit (CVS-ICU) and the coronary intensive care unit (CICU). A descriptive study. Place and Duration of the Study: CVS-ICU and CICU, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkiye, from January 2024 to January 2025. Adult patients (≥18 years) hospitalised for ≥24 hours, diagnosed with ARC (eGFR ≥130 mL/min/1.73 m2), and receiving antibiotics were included. Dosing appropriateness was assessed based on UpToDate® recommendations. ARC risk was stratified using the ARC scoring system. Data were analysed using descriptive statistics, chi-square test, and Mann-Whitney U test. Of the 3,334 screened patients, 83 (2.5%) met ARC criteria; 57 received antibiotics and were included in the analysis. At least one dosing error was identified in 84.2% of cases, mostly underdosing (73.1%). The most common antibiotics were cefazolin (42.6%), ampicillin-sulbactam (14.6%), and daptomycin (7.3%). A high ARC risk score was associated with a greater likelihood of dosing errors (90.4% vs. 66.6%; OR = 4.7, p = 0.044). Patients with dosing errors were younger (median 25.5 vs. 50 years, p = 0.004) and received more antibiotics (p = 0.038). Although ARC was uncommon, dosing errors were frequent. Early recognition of ARC and individualised dosing are critical to optimise therapy in ICU patients. Augmented renal clearance, Antibiotic dosing, Cardiovascular surgery intensive care unit, Coronary intensive care unit, Dose adjustment.

PMID 42698253
阅读全文 →
PubMedJournal of plastic, reconstructive & aesthetic surgery : JPRAS2026-09-04

Prophylactic antibiotic use after cleft lip repair: Does it reduce complications, and is it necessary?

Gharavi Aidin A, Wan Rou R, Haile Dawit D, Garcia Jose Castro JC et al.

Cleft lip repair (CLR) is one of the most common reconstructive surgeries performed for congenital conditions. Although perioperative surgical antibiotic prophylaxis (SAP) is commonly used, evidence supporting its benefit in CLR is limited. We performed a retrospective cohort study using the 2021-2024 American College of Surgeons Pediatric SAP Data Files. Infants ≤12 months who underwent primary CLR were categorized into three groups: no SAP, SAP without postoperative continuation, and SAP with continued postoperative IV antibiotics. Primary outcomes were 30-day SSI and readmission, which was evaluated using Firth penalized logistic regression. A prespecified subanalysis was performed in patients who underwent bilateral CLR (BCLR). A total of 4,966 patients met the inclusion criteria: 475 (9.6%) received no SAP, 3,250 (65.4%) received SAP without continuation, and 1,241 (25.0%) received SAP with postoperative continuation. SAP was administered to 90.4% of the patients, the most commonly used SAP was cefazolin (87.2%). The overall SSI rate was 0.7%. On multivariable analysis, neither SAP without continuation (OR 0.69, 95% CI 0.27-2.19, p=0.49) nor SAP with continuation (OR 0.61, 95% CI 0.20-2.12, p=0.41) were associated with decreased SSI. SAP was also not associated with reduced readmissions or composite complications. In the BCLR subanalysis, both SAP groups were significantly associated with decreased odds of SSI (OR 0.19 and 0.17, respectively; both p<0.05). In this multicenter cohort, SAP was not associated with reduced complications in the overall CLR population. However, patients who underwent BCLR and received SAP had significantly lower odds of SSI, indicating that this higher-risk subgroup may benefit from prophylaxis.

PMID 42697031
阅读全文 →
PubMedEBioMedicine2026-09-04

Discovering repurposable drugs for Alzheimer's disease and related dementias: target trial emulation using decentralised real-world data.

Wu Qiong Q, Li Lu L, Lei Yuqing Y, Zhou Ting T et al.

Alzheimer's disease and related dementias (ADRD) affect nearly 6.9 million Americans, with the number expected to triple by 2050, while disease-modifying therapies remain unavailable. Drug repurposing, which identifies new indications for already approved medications, offers a more efficient and cost-effective pathway to accelerate development of effective therapies for ADRD. The aim of this study is to identify potential drug repurposing signals by systematically screening routinely prescribed drugs for associations with progression from mild cognitive impairment (MCI) to ADRD. We conducted a multi-site target trial emulation using electronic health record (EHR) data from four decentralised databases: INSIGHT Clinical Research Network, OneFlorida + Clinical Research Consortium, the University of Pennsylvania Health System, and Yale New Haven Health System. We performed an independent validation using EHR data from the TriNetX Research Network and a genetic risk-stratified sensitivity analysis in the Penn Medicine BioBank (PMBB) database. Eligible participants were adults aged 50 years or older at the time of MCI diagnosis, with no prior diagnosis of ADRD and no prior use of the trial drugs. Initiation of each of 181 routinely prescribed drugs was compared with two active control groups defined by initiation of supplements or cardiovascular medications. Risk ratios (RRs) and 95% CIs were estimated using a federated target trial emulation framework (LATTE) with stabilised inverse probability of treatment weighting and Poisson regression. A total of 122,972 eligible patients were identified from the four decentralised databases, 335,506 patients identified from the TriNetX network for validation and 898 from PMBB database. Federated, multi-site target trial emulation identified 20 drug repurposing hypotheses with statistically significant protective effects, including anti-inflammatory and pain-modulating agents (celecoxib: RR 0.43; 95% CI: 0.23-0.81; dexamethasone RR 0.46; 95% CI: 0.29-0.73; gabapentin: RR 0.55; 95% CI: 0.36-0.83; ketorolac: RR 0.50; 95% CI: 0.31-0.80; methylprednisolone: RR 0.43; 95% CI: 0.24-0.76; prednisone: RR 0.48; 95% CI: 0.28-0.83; pregabalin: RR 0.53; 95% CI: 0.35-0.79), antimicrobial and microbiome-associated agents (cefazolin: RR 0.62; 95% CI: 0.45-0.84; clavulanate: RR 0.56; 95% CI: 0.44-0.71; fluconazole: RR 0.36; 95% CI: 0.23-0.58), neuromodulators and adrenergic agents (epinephrine: RR 0.42; 95% CI: 0.31-0.56; propranolol: RR 0.56; 95% CI: 0.37-0.85; salmeterol: RR 0.49; 95% CI: 0.32-0.74; tizanidine: RR 0.29; 95% CI: 0.14-0.57), vascular, metabolic, and hormonal modulators (empagliflozin: RR 0.29; 95% CI: 0.17-0.50; oestradiol: RR 0.47; 95% CI: 0.28-0.81; ezetimibe: RR 0.69; 95% CI: 0.52-0.91; sodium bicarbonate: RR 0.49; 95% CI: 0.29-0.84; spironolactone: RR 0.43; 95% CI: 0.31-0.60), and histamine-related and gastrointestinal agents (famotidine: RR 0.64; 95% CI: 0.55-0.74). Results were consistent in the independent validation using TriNetX network and sensitivity analysis in PMBB database. 20 widely used medications may be associated with reduced progression from MCI to ADRD and represent promising candidates for clinical evaluation as repurposed therapies for dementia. National Institutes of Health.

PMID 42697072
阅读全文 →
PubMedInfection2026-09-03

A retrospective study of alternative antibiotics for prophylaxis of the Group B Streptococcus maternal-fetal disease.

Guo Hongxia H, Huang Wanqiu W, Chen Cheng C, Sun Bo B

This study aimed to evaluate the effectiveness and safety of cefazolin prophylactic regimen versus standard penicillin treatment in pregnant women colonized with GBS(Group B Streptococcus), and further analyzed the timing of intrapartum antibiotic prophylaxis. We retrospectively analyzed the singleton pregnant women with GBS colonization at 35-37 weeks of gestation in Shenzhen Baoan Women's and Children's Hospital between September 2018 and January 2024. 2653 pregnant women received standardized penicillin prophylaxis and 2418 pregnant women received alternative cefazolin prophylaxis in labor. Maternal and neonatal outcomes were compared between the two different intrapartum antibiotic prophylaxis (IAP) groups. No significant differences were found in postpartum hemorrhage, amniotic fluid fecal contamination, delivery assistance, neonatal sepsis, neonatal asphyxia and Apgar score between Penicillin group and Cefazolin group (P > 0.05). In terms of chorioamnionitis, neonatal pneumonia, cesarean section, neonatal jaundice and NICU admission, the cefazolin group showed significantly lower rates than that of penicillin group(P < 0.05). The incidence of chorioamnionitis, transfer to cesarean section and NICU admission in both penicillin and cefazolin IAP subgroup of more than 4 h were lower than that of less than or equal 4 h, however with no significantly difference when using cefazolin about chorioamnionitis. Our study shows that cefazolin is effective and safe as penicillin in preventing maternal-fetal GBS infection and may be used as an alternative antibiotics. In addition, it is supposed that IAP should be administered during labor for at least 4h prior to delivery.

PMID 42690541
阅读全文 →

注册免费账户还可查看另外 6267 篇文献

免费注册查看全部文献 →

了解更多cefazolin dibenzylamine